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Abstract
Radium-223 was minimally myelosuppressive. Multivariate analyses of data from ALSYMPCA patients identi-
ﬁed baseline factors that may increase hematologic toxicity risk with radium-223. Extent of disease and degree
of prostate-speciﬁc antigen elevation were predictive of grade 2-4 anemia; prior docetaxel, and decreased
hemoglobin and platelets were predictive of grade 2-4 thrombocytopenia. Patients with these factors should
be closely monitored during radium-223 therapy.
Background: Myelosuppression is common in patients with progressive castration-resistant prostate cancer and
bone metastases. Radium-223 prolongs overall survival in these patients but may cause myelosuppression; under-
standing risk factors will improve clinical decision making. We describe hematologic safety of radium-223 in
ALSYMPCA and post hoc analyses identifying patients at increased risk for hematologic toxicity. Patients and
Methods: Hematologic parameters and adverse events were analyzed. Multivariate analyses assessing baseline risk
factors for hematologic toxicities were performed separately for radium-223 and placebo patients. Results: Nine
hundred one patients received radium-223 (n ¼ 600) or placebo (n ¼ 301); 65% of radium-223 and 48% of placebo
patients had the full 6 cycles. Grade 3/4 thrombocytopenia was more common in radium-223 versus placebo patients
(6% vs. 2%). Logistic regression analyses identiﬁed signiﬁcant baseline predictors for grade 2-4 hematologic toxicities
related to radium-223 treatment: extent of disease (6-20 vs. < 6 bone metastases; odds ratio [OR] ¼ 2.76; P ¼ .022)
and elevated prostate-speciﬁc antigen (OR ¼ 1.65; P ¼ .006) for anemia; prior docetaxel (OR ¼ 2.16; P ¼ .035),
decreased hemoglobin (OR ¼ 1.35; P ¼ .008), and decreased platelets (OR ¼ 1.44; P ¼ .030) for thrombocytopenia.
Neutropenia events were too few in placebo patients for a comparative analysis. There were no signiﬁcant associa-
tions between hematologic toxicities and number of radium-223 injections received (4-6 vs. 1-3). Conclusion:
Radium-223 has a favorable safety proﬁle with a low myelosuppression incidence. Understanding baseline factors
associated with myelosuppression may assist clinicians in avoiding severe myelosuppression events with radium-223.
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article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Alpha-emitting radiopharmaceutical, Anemia, Castration-resistant prostate cancer, Myelotoxicity,
ThrombocytopeniaPresented in part at the ASCO 2013 Annual Meeting, May 31-June 4, 2013, Chicago,
IL; European Cancer Congress 2013 (ECCO-ESMO-ESTRO), September 27-October
1, 2013, Amsterdam, Netherlands; Annual Congress of the European Association of
Nuclear Medicine, October 19-23, 2013, Lyon, France; 24th International Prostate
Cancer Update, February 19-22, 2014, Vail, CO; and ASTRO’s 56th Annual Meeting,
September 14-17, 2014, San Francisco, CA.
1Comprehensive Cancer Centers of Nevada, Department of Medical Oncology, Las
Vegas, NV
2Weston Park Hospital, Department of Oncology, Shefﬁeld, UK
3Washington University School of Medicine, Radiation Oncology, St Louis, MO
4Karolinska University Hospital, Department of Oncology, Stockholm, Sweden
5Queen’s University, Centre for Cancer Research and Cell Biology, Belfast, UK
6Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Academic
Urology Unit, Sutton, UK
7Umeå University, Department of Radiation Sciences, Umeå, Sweden
8Statisticon AB, Biostatistics Department, Uppsala, Sweden
9Bayer HealthCare Pharmaceuticals, Global Medical Affairs Oncology, Whippany, NJ
10Bayer HealthCare Pharmaceuticals, US Medical Affairs Oncology, Whippany, NJ
11Tulane Cancer Center, Departments of Medicine and Urology, New Orleans, LA
Submitted: Jun 6, 2016; Revised: Jul 26, 2016; Accepted: Jul 30, 2016
Address for correspondence: Nicholas J. Vogelzang, MD, Comprehensive Cancer
Centers of Nevada, 3730 South Eastern Ave, Las Vegas, NV 89169
Fax: (702) 952-3453; e-mail contact: Nicholas.Vogelzang@USOncology.com
1558-7673/ª 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.clgc.2016.07.027 Clinical Genitourinary Cancer Month 2016 - 1
2 - Cli
Safety of Radium-223 in CRPCIntroduction unsuitable for or declined docetaxel. Patients must have had
More than 90% of men with metastatic castration-resistant
prostate cancer (mCRPC) have bone metastases,1 often with pain
and bone fractures.1-4 Anemia accompanies advancing disease and is
a risk factor for poor outcome in mCRPC.5,6 Docetaxel and cab-
azitaxel chemotherapy, particularly when given late in the course of
the disease, may cause anemia.7-9 Radium-223 may also cause
anemia and thrombocytopenia, which can mimic or exist concur-
rently with bone marrow failure. Thus, the ability to identify po-
tential risk factors for hematologic toxicity before radium-223
initiation is important, so high-risk patients can be monitored for
treatment modiﬁcations.
Radium-223 dichloride (radium-223), approved for patients with
CRPC and symptomatic bone metastases,10,11 is a calcium mimetic
binding to newly formed bone in areas of bone metastases.12 The
high linear energy transfer of emitted alpha particles causes pre-
dominantly nonrepairable double-stranded DNA breaks in tumor
cells,12-14 and the large size of the alpha particle results in a short
path length and localized area of intense tissue destruction (< 100
mm; 2-10 cell diameters). Unlike beta particleeemitting radionu-
clides indicated for pain palliation, the short range of therapeutic
radium-223 alpha particles spares distant hematologic tissue, which
may result in fewer hematologic adverse events (AEs).13 Early
radium-223 experience indicated a low incidence of clinically sig-
niﬁcant myelosuppression with single injections of up to 250 kBq/
kg15 or 4 doses of 50 kBq/kg (55 kBq/kg following the National
Institute of Standards and Technology [NIST] update16) over 12
weeks.17
ALSYMPCA, a phase III, randomized, double-blind, placebo-
controlled multinational study compared efﬁcacy and safety of
radium-223 plus best standard of care (BSoC) versus placebo plus
BSoC in patients with CRPC and symptomatic bone metastases.
Radium-223 signiﬁcantly improved median overall survival by 3.6
months (hazard ratio [HR] ¼ 0.70; 95% conﬁdence interval, 0.58-
0.83; P < .001) versus placebo and showed favorable safety with
low myelosuppression.11,18 Based on these results, radium-223 was
approved for CRPC patients with symptomatic bone metastases and
no visceral metastases.
This report further examines radium-223 hematologic safety in
ALSYMPCA, presenting all hematologic AEs with statistical com-
parisons of select hematologic AEs between treatment groups,
detailed post hoc analyses identifying baseline factors that may in-
crease risk for hematologic toxicity, and further characterization of
patients who experienced grade 3 or 4 thrombocytopenia and
pancytopenia or bone marrow failure.
Methods
Patients
ALSYMPCA trial design with full enrollment criteria has been
reported.11 Enrolled patients had symptomatic CRPC and  2
bone metastases with no visceral metastases, elevated and rising
prostate-speciﬁc antigen (PSA) level, Eastern Cooperative Oncology
Group performance status  2, life expectancy  6 months, and
adequate baseline hematologic, renal, and liver function. Adequate
hematologic function was deﬁned as absolute neutrophil count 
1.5  109/L, platelet count  100  109/L, and hemoglobin 
10.0 g/dL. Patients either had previous docetaxel treatment or werenical Genitourinary Cancer Month 2016symptomatic disease, ie, requiring regular opioid or nonopioid
analgesic use or having received external beam radiation therapy
(EBRT) for bone pain within 12 weeks before randomization.
Chemotherapy, blood transfusions, and erythropoietin stimulants
were not permitted within 4 weeks of randomization; hemibody
external radiotherapy and radiopharmaceuticals within 24 weeks
were not allowed.
The trial was conducted in accordance with the Declaration of
Helsinki. All patients provided written informed consent.
Study Design
Patients were randomized 2:1 to radium-223 50 kBq/kg (55
kBq/kg following the NIST update16) plus BSoC or placebo plus
BSoC every 4 weeks for 24 weeks (6 injections). BSoC was deﬁned
as routine care provided at each center and included EBRT for pain
as indicated. Patients had received docetaxel or were not healthy
enough to receive the drug, they declined it, or it was not available.
Data were not collected on the number of previous docetaxel doses
or the cumulative docetaxel dose received. Concomitant chemo-
therapy was not permitted during treatment. The primary end point
was overall survival; safety was a secondary end point. The planned
follow-up period was 3 years.
Assessments
Safety was assessed by incidence and severity of hematologic and
nonhematologic treatment-emergent AEs, clinical chemistry, elec-
trocardiogram, and physical examination; relationship to treatment
was reported as judged by the investigator. All AEs occurring after
randomization and within 12 weeks after the last study-drug in-
jection were reported and evaluated for potential relationship to
study drug. AEs were graded per Common Terminology Criteria for
Adverse Events (CTCAE), version 3.0. Grade 3/4 thrombocyto-
penia was based on investigator’s reporting of AEs, which included
relevant symptoms, and not based solely on platelet laboratory
values.
Blood samples for hematology were to be analyzed in the local
laboratory and evaluated within 24 hours before each study-drug
administration.
Statistical Analysis
Statistical methods used in ALSYMPCA have been
described.11,19 Descriptive statistics (n, mean, standard deviation,
minimum, median, and maximum values) were presented for
clinical laboratory tests (hematology and clinical biochemistry) and
their changes from baseline. Post hoc analyses of hematology data
included time to ﬁrst blood transfusion, patients with grade 3 or 4
thrombocytopenia, and patients with preferred term pancytopenia
or bone marrow failure. Cox regression analysis was used to assess
time to ﬁrst blood transfusion. Grade 3/4 thrombocytopenia
duration was assessed from time of initial recording to resolution,
patient death, or close of study database. Fisher’s exact test was used
to compare hematologic AE rates for radium-223 versus placebo
groups, and Wilcoxon rank sum test for differences in laboratory
values between groups at different time points.
Post hoc analyses of ALSYMPCA patients treated with radium-
223 versus placebo were performed separately using logistic
Nicholas J. Vogelzang et alregression analysis to explore baseline risk factors for grade 2-4
hematologic toxicity; patients with grade 3/4 hematologic toxicity
were too few for meaningful analysis. Baseline factors prespeciﬁed in
ALSYMPCA, including additional baseline covariates based on
clinical relevance to the hematologic toxicity, were used in the
regression analysis. Baseline factors identiﬁed as signiﬁcantly
correlated with grade 2-4 anemia, neutropenia, and thrombocyto-
penia in the radium-223 subset, but not placebo subset, were
considered likely to predict radium-223 treatment effect on AE
occurrence. Analyses were performed in 3 steps. First, univariate
logistic regression was performed for each potential risk factor.
Second, variables with P < .10 in the univariate analysis were
entered into the multivariate analysis. Baseline hemoglobin, neu-
trophils, and platelets were added even if univariate P was > .10,
given that these factors are expected to correlate with respective
hematologic AEs. Third, the model was subject to a stepwise pro-
cedure, the optimal model deﬁned as that with the smallest Akaike
information criteria (AIC) value.20 Given the exploratory nature of
the analysis, adjustments for multiple comparisons were not made.
Statistical programming and analyses used SAS 9.2 (SAS Institute,
Cary, NC) and R 3.0.1 (R Foundation for Statistical Computing,
Vienna, Austria); analyses were based on safety population.Figure 1 CONSORT Flow Chart Indicating Disposition of Patients in A
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Abbreviations: BSoC ¼ best standard of care; ITT ¼ intent to treat.Results
Patients
ALSYMPCA intent-to-treat (ITT) population included 921 pa-
tients randomized to radium-223 plus BSoC or placebo plus BSoC.
Safety population included 600 radium-223 and 301 placebo pa-
tients who received  1 study-drug injection (Figure 1). Baseline
clinical and demographic characteristics were well balanced between
groups (Table 1); 387/600 (65%) radium-223 and 145/301 (48%)
placebo patients received all 6 study-drug injections (Supplemental
Table 1 in the online version).
Dynamics of Hematologic Laboratory Values
Hemoglobin showed modest decreases in both treatment groups,
persisting through follow-up; differences between radium-223 and
placebo groups were signiﬁcant only during follow-up (weeks 44,
51, 69). For radium-223 patients, median hemoglobin decreased
from 12.2 g/dL at baseline to 11.4 g/dL at treatment end (week 24)
and 10.8 g/dL at follow-up visit 2 (week 44). Among placebo pa-
tients, hemoglobin decreased from 12.1 g/dL at baseline to 11.6 g/
dL and 11.2 g/dL at weeks 24 and 44, respectively (Figure 2A).
Median absolute neutrophil counts (ANCs) decreased modestly in
radium-223 patients with some recovery during follow-up. ANCLSYMPCA. aEighteen Patients Were Withdrawn From Study Before
d No Treatment and Had Missing Dates of Withdrawal. b1 Patient
ek 0. This Patient Is Included as Randomly Assigned in ITT
3 Group for Safety Population. cPatients who Discontinued
Were Not Regarded as Withdrawn From Study. Study Was
ot Sum to Total Number Treated. dPatients who Withdrew Before
thdrawn Early From Study. ePatients in Placebo Group who
linded Were Not Regarded as Having Discontinued Treatment or
 placebo + BSoC
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Table 1 Patient Demographics and Baseline Characteristics
(Safety Population; N [ 901)
Characteristica
Radium-223
(N [ 600)
Placebo
(N [ 301)
Age
Median (range), years 71 (49-90) 71 (44-89)
>75 years, n (%) 169 (28) 88 (29)
Race, n (%)
White 562 (94) 284 (94)
Total Alkaline Phosphatase
Level, n (%)
<220 U/L 345 (58) 165 (55)
220 U/L 255 (43) 136 (45)
Current Use of Bisphosphonates at
Study Entry, n (%)
Yes 244 (41) 120 (40)
No 356 (59) 181 (60)
Prior Docetaxel Use, n (%)
Yes 347 (58) 171 (57)
No 253 (42) 130 (43)
ECOG PS, n (%)b
0 162 (27) 77 (26)
1 366 (61) 183 (61)
2 72 (12) 40 (13)
WHO Ladder for Cancer Pain, n (%)
0-1 (no pain or mild pain; no opioid use) 263 (44) 138 (46)
2 (moderate pain; occasional opioid use) 148 (25) 78 (26)
3 (severe pain; regular daily opioid use) 189 (32) 85 (28)
Extent of Disease, n (%)c
<6 metastases 100 (16) 38 (12)
6-20 metastases 262 (43) 147 (48)
>20 metastases or superscand 249 (41) 121 (39)
EBRT Within 12 Weeks of
Screening, n (%)
Yes 98 (16) 46 (15)
No 502 (84) 255 (85)
Biochemical Values, Median (Range)c,e
Albumin, g/L 40 (24-53) 40 (23-50)
Total alkaline phosphatase, U/L 211 (32-6431) 223 (29-4805)
Lactate dehydrogenase, U/L 315 (76-2171) 336 (132-3856)
Prostate-speciﬁc antigen, mg/L 146 (4-6026) 173 (2-14,500)
Hematologic Values, Median (Range)c,e
Hemoglobin, g/dL 12.2 (9-16) 12.1 (9-16)
Neutrophils (absolute), 109/L 4.5 (1-17) 4.6 (1-14)
Platelets, 109/L 244 (69-645) 240 (51-580)
Lymphocytesc (absolute), 109/L 1.3 (0.3-8) 1.4 (0.1-4)
Abbreviations: EBRT ¼ external beam radiotherapy; ECOG PS ¼ Eastern Cooperative Oncology
Group performance status; ITT ¼ intent to treat; WHO ¼ World Health Organization.
aPercentages may not sum to 100% due to rounding.
bValue recorded at screening.
cBased on the ITT population (radium-223, n ¼ 614; placebo, n ¼ 307).
dSuperscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without
renal and background activity.
eValue recorded at week 0. If this value was missing, then the value recorded at screening was used.
The normal valueswere as follows: albumin, 36-45 g/L; total alkaline phosphatase, 35-105U/L; lactate
dehydrogenase, 115-225 U/L; prostate-speciﬁc antigen, 0-3.999mg/L; hemoglobin, 13.4-17.0 g/dL;
neutrophils (absolute), 2-7.5  109/L; platelets, 150-350 109/L; lymphocytes, 1-4  109/L.
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4 - Clinical Genitourinary Cancer Month 2016remained constant for placebo patients, with little change from
baseline. Signiﬁcant differences versus placebo were observed over
most of the treatment period: with radium-223, baseline was 4.5 
109/L; week 24, 3.3  109/L; and week 44, 3.9  109/L; placebo
had corresponding values of 4.6  109/L, 4.5  109/L, and 4.3 
109/L, respectively (Figure 2B). Platelet counts for both groups
decreased over the treatment period, with larger decreases among
radium-223 patients and recovery during follow-up. Between-group
platelet count differences were statistically signiﬁcant over most of
the treatment period: with radium-223, baseline was 244  109/L,
week 24 was 202  109/L, and week 44 was 216  109/L; placebo
had corresponding values of 240  109/L, 232  109/L, and 218 
109/L, respectively (Figure 2C).
Hematologic AEs
No signiﬁcant differences existed between treatment groups in
anemia rates for all grades (radium-223, 31%; placebo, 31%) or
grade 3/4 (radium-223, 13%; placebo, 13%). Similarly, grade 3/4
neutropenia rates were not signiﬁcantly different (radium-223,
2%; placebo, 1%), although signiﬁcance was reached for all grades
(radium-223, 5%; placebo, 1%; P ¼ .002). Thrombocytopenia
rates reached signiﬁcance for all-grade (radium-223, 12%; placebo,
6%; P ¼ .005) and grade 3/4 events (radium-223, 6%; placebo,
2%; P ¼ .005). One patient with grade 5 thrombocytopenia
(15  109/L), believed related to radium-223, died from pneu-
monia with hypoxemia and no evidence of bleeding (Table 2).
Additional hematologic AEs observed in  1 patient with radium-
223 treatment are shown in Table 2. Grade 3 febrile neutropenia
occurred in 1/600 (< 1%) radium-223 patient and 1/301 (< 1%)
placebo patient. One radium-223 patient experienced grade 5
bone marrow failure (hemoglobin 7.0 g/dL, platelets 53  109/L,
red cells 2.3  1012/mm3, leukocytes 5.8  109/mm3), which the
investigator considered not study-drug related; diagnosis was based
on laboratory measurements; no bone marrow biopsy was per-
formed. This patient died of prostate cancer with skeletal
metastases.
Blood Transfusions
Similar proportions of radium-223 (42%) and placebo (39%)
patients required blood transfusions from randomization to study
end. Platelets were more frequently administered to radium-223
patients (Table 3). There was no signiﬁcant difference between
radium-223 and placebo patients in time to ﬁrst blood transfusion
(HR ¼ 0.92; 95% conﬁdence interval, 0.74-1.115; P ¼ .452)
(Supplemental Figure 1 in the online version).
Analyses of Baseline Risk Factors for Grade 2-4
Hematologic AEs
Results from univariate and multivariate analyses for radium-223
and placebo patients are shown in Supplemental Tables 2-5 in the
online version. Final optimal stepwise models for radium-223 and
placebo patients are shown in Table 4 and Supplemental Table 6 in
the online version, respectively. Some variables included in the
univariate analysis, such as EBRT within 12 weeks of screening, did
not reach signiﬁcance (P < .10) as required for inclusion in the
multivariate analysis and the stepwise model.
Figure 2 Box Plots of Hemoglobin (A), Neutrophil (B), and Platelet (C) Values During ALSYMPCA (Safety Population; N[ 901). Lower
and Upper Boundaries of Boxes Indicate Upper and Lower Quartiles; Horizontal Lines Within Boxes Indicate Medians. Dashed
Lines Extend to Extreme Data Points, No More Than 1.5 Times Interquartile Range From Box. More Extreme Data Points Are
Identiﬁed as Points. Solid Horizontal Line Represents Median Values Obtained at Screening. One Extreme Outlier Was
Removed From Radium-223 Week 33 Data (> 65 3 109/L) for Neutrophils. P Values Are Shown Where Differences Between
Median in Radium-223 and Placebo Groups for Individual Time Points Were Signiﬁcantly Different (P £ .05)
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Nicholas J. Vogelzang et alThe risk-assessment model for grade 2-4 anemia included 169/
567 (30%) radium-223 patients and 78/290 (27%) placebo patients
with events (Table 4 and Supplemental Table 6 in the online
version). Baseline factors signiﬁcantly associated with increased risk
for radium-223 patients were greater extent of disease (6-20 vs. < 6
metastases; odds ratio [OR] ¼ 2.76; P ¼ .022) and higher PSA
(OR ¼ 1.65; P ¼ .006). Risk of grade 2-4 anemia was not statis-
tically signiﬁcant among those who received 4-6 versus 1-3 radium-
223 injections (OR ¼ 1.57; P ¼ .097). Baseline factors that were
signiﬁcant in both radium-223 and placebo patients, and therefore
not considered risk factors likely to predict radium-223 treatment
effect on anemia occurrence, included extent of disease (> 20 vs. <
6 metastases), higher baseline total alkaline phosphatase, and lower
baseline hemoglobin levels (Table 4 and Supplemental Table 6 in
the online version).The grade 2-4 neutropenia model included 24/591 (4%) radium-
223 patients with events; too few placebo patients (3/301 [1%]) had
events for comparative analysis to assess relationship with treatment
effect. In radium-223 patients, risk for grade 2-4 neutropenia
increased with prior docetaxel therapy (OR ¼ 3.44; P ¼ .020),
World Health Organization (WHO) ladder cancer pain score
(2 vs. 3) (OR ¼ 3.58; P ¼ .042), and decrease in baseline
neutrophil counts (OR ¼ 2.01; P < .001). No signiﬁcant associ-
ation existed among radium-223 patients who received 4-6 versus 1-
3 radium-223 injections (OR ¼ 1.14; P ¼ .837) (Table 4).
The grade 2-4 thrombocytopenia model included 53/573 (9%)
radium-223 patients and 11/292 (4%) placebo patients with events
(Table 4 and Supplemental Table 6 in the online version). The
small number of events among placebo patients reduces conﬁdence
in results for this group. Prior docetaxel therapy (OR ¼ 2.16;Clinical Genitourinary Cancer Month 2016 - 5
Figure 2 Continued
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6 - CliP ¼ .035) and decreases in baseline hemoglobin (OR ¼ 1.35;
P ¼ .008) or platelets (OR ¼ 1.44; P ¼ .030) were associated with
signiﬁcantly increased risk of grade 2-4 thrombocytopenia among
radium-223 patients. Number of radium-223 injections (4-6 vs.
1-3) was not associated with increased risk (OR ¼ 0.77; P ¼ .475).
Baseline factors that were signiﬁcant in both radium-223 and
placebo patients, and therefore not considered risk factors likely to
predict radium-223 treatment effect on thrombocytopenia occur-
rence, included increased age and higher baseline PSA.
Patients With Grade 3 or 4 Thrombocytopenia
Compared with baseline characteristics of the ALSYMPCA safety
population (Table 1), the small group of 38 radium-223 and 6
placebo patients who developed grade 3/4 thrombocytopenia had a
higher percentage with prior docetaxel (31/38 [82%] radium-223
and 5/6 [83%] placebo patients) (Supplemental Table 7 in the
online version). Other apparent differences included more extensive
disease (> 20 metastases or superscan) (23/38 [61%] radium-223
and 3/6 [50%] placebo patients) and higher baseline median PSA
(344 mg/L for radium-223 and 1472 mg/L for placebo).
Platelet counts gradually decreased, reaching grade 3/4 at median
19 weeks (range 2.4-38 weeks) relative to ﬁrst radium-223 injection
(Figure 3A); 28/38 patients (74%) received  4, and 13/38 (34%)
received all 6 radium-223 injections. In 9/38 (24%) patients,
platelet counts were  350  109/L at screening; more than half
had  230  109/L. Patients with higher screening platelet counts
( 223  109/L) and rapid platelet decline during treatment tended
to have more advanced disease (ALP  220 U/L), more bone pain,
and more bone metastases (data not shown). Only 1/38 (3%) pa-
tient recovered to  150  109/L with no apparent relationship to
screening platelet count. A similar pattern was seen for 6 placebo
patients (Figure 3B) with no recovery during follow-up.nical Genitourinary Cancer Month 2016The majority of radium-223 patients with grade 3/4 thrombo-
cytopenia (35/38 [92%]) had late onset, after at least the third in-
jection, which may suggest a cumulative effect and mechanism
different from that seen with placebo (Figure 3C).
Grade 3/4 thrombocytopenia duration was < 4 weeks for all 6/6
(100%) placebo patients and for 15/38 (39%) radium-223 patients.
For 10/38 (26%) radium-223 patients, events had longer duration,
4 to 12 weeks; for 13/38 (34%) patients, duration was > 12 weeks
(Figure 3D).
Treatment delays were seen in 16/38 (42%) radium-223 patients
with grade 3/4 thrombocytopenia; AEs were the most common
reason (14 patients), including anemia (n ¼ 5), thrombocytopenia
(n ¼ 2), neutropenia (n ¼ 1), and other AE-related reasons (n ¼ 6).
Despite treatment delays due to AEs, 6/14 (43%) radium-223 pa-
tients completed all 6 injections, including both patients with delay
due to grade 3/4 thrombocytopenia.
Pancytopenia or Bone Marrow Failure
Pancytopenia was reported for 12/600 (2%) radium-223 patients
and bone marrow failure for 1/600 (< 1%) radium-223 and no
placebo patients. Among 13 radium-223 patients with pancytopenia
or bone marrow failure, 5/13 (39%) did not complete all 6 study
injections. These 13 patients, versus overall ITT population
(Supplemental Table 8 in the online version), show a higher pro-
portion with prior docetaxel exposure (85% vs. 57% respectively)
and higher baseline PSA values (344 mg/L vs. 146 mg/L,
respectively).
Discussion
Radium-223 is well tolerated with minimal myelotoxicity in
patients with CRPC and bone metastases,11,15,17,18 comparing well
in safety and efﬁcacy with other therapies for these patients.7,21-24
Table 2 Hematologic AEs in ALSYMPCA (Safety Population; N [ 901)
Patients With Hematologic AEs, N (%)
Radium-223 (N [ 600) Placebo (N [ 301)
All Grades Grade 2 Grade 3 Grade 4 Grade 5a All Grades Grade 2 Grade 3 Grade 4 Grade 5a
Hematologic AEs Occurring in ‡5% of Patients
Anemia 187 (31)b 97 (16) 66 (11) 11 (2) 0 92 (31) 44 (15) 37 (12) 2 (1) 1 (<1)
Neutropenia 30 (5) 12 (2) 9 (2) 4 (1) 0 3 (1) 1 (<1) 2 (1) 0 0
Thrombocytopenia 69 (12) 19 (3) 20 (3) 18 (3) 1 (<1) 17 (6) 7 (2) 5 (2) 1 (<1) 0
Additional Hematologic AEs Occurring in ‡1 Radium-223 Patient
Leukopenia 25 (4) 14 (2) 7 (1) 1 (<1) 0 1 (<1) 0 1 (<1) 0 0
Lymphopenia 5 (1) 2 (<1) 3 (1) 0 0 1 (<1) 0 1 (<1) 0 0
Pancytopenia 12 (2)b 4 (1) 4 (1) 3 (1) 0 0 0 0 0 0
AE P (All Grade AEs)c P (Grade 3 and 4 AEs)c
Anemia NS NS
Neutropenia .002 NS
Thrombocytopenia .005 .005
Abbreviations: AE ¼ adverse event; NS ¼ not statistically signiﬁcant (P > .05).
aOnly 1 grade 5 hematologic AE was considered possibly related to the study drug: thrombocytopenia in 1 patient in the radium-223 group who died from pneumonia with hypoxemia, with n evidence of bleeding.
bOne patient had both a missing and grade 3 AE grade level and is included in N (%). Within a MedDRA system organ class and preferred term, a missing Common Terminology Criteria (CTC) gr e is taken as the “worst” case unless the nonmissing CTC grade is 5; then the
maximum toxicity is CTC grade 5.
cP values were calculated from Fisher’s exact tests comparing the AE rates between radium-223 and placebo groups.
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8 - Clinical Genitourinary Cancer Month 2016Although there were no signiﬁcant associations between he-
matologic toxicities and number of radium-223 injections
received, it is important to note that patients were supported
with transfusions as needed and as described in the prescribing
information.10 A high rate of anemia in patients with CRPC
and bone metastases has been reported.5,6 In ALSYMPCA,
anemia was the most common hematologic toxicity; its fre-
quency and severity were the same with radium-223 and
placebo and likely due to disease burden, although concomi-
tant BSoC treatment effects were not accounted for. Median
baseline values for hemoglobin (z12 g/dL) suggest that many
or most patients were anemic at study entry, and logistic
regression analysis showed correlations between grade 2-4
anemia and factors related to extent of disease (eg, elevated
PSA and higher extent of disease) in radium-223 patients.
Current prescribing information recommends that hemoglobin
be  10 g/dL prior to ﬁrst radium-223 administration.
Ongoing protocols allow hemoglobin  8 g/dL (with
transfusions).
Neutropenia was more common in radium-223 patients.
Neutrophil counts decreased with radium-223 treatment, but grade
3/4 events were rare and too few with placebo for comparison to
assess the relationship with treatment effect in the logistic regression
analysis.
Thrombocytopenia was more common in radium-223 patients,
and risk increased with prior docetaxel and decreased baseline he-
moglobin and platelets. Its association with prior docetaxel use
is consistent with earlier analysis of ALSYMPCA patients showing a
3-fold greater incidence of grade 3/4 thrombocytopenia among
radium-223 patients previously exposed to docetaxel versus those
not exposed (9% vs. 3%).25 Prudent management requires blood
count evaluation before each radium-223 dose, with minimum
values deﬁned as a threshold for continued treatment, per current
prescribing information (Supplemental Table 9 in the online
version).10 Prior to the ﬁrst injection, ANC should be  1.5  109/L
and platelets should be  100  109/L. Prior to each subsequent
injection, ANC should be  1.0  109/L and platelets should
be  50  109/L. If there is no recovery to these values within 6 to
8 weeks after the last injection despite supportive care, radium-223
should be discontinued.
No differences between radium-223 and placebo groups exists in
frequency of blood transfusions or time to ﬁrst blood transfusion, a
ﬁnding that is noteworthy in this mCRPC population.
Clinicians are advised to balance beneﬁt and risk when deter-
mining whether to continue treatment. It is acceptable to delay
treatment; delays allowing completion of 6 radium-223 cycles may
be key to ensuring maximum treatment beneﬁt. It is important to
note that thrombocytopenia onset was slow and did not warrant
abrupt discontinuation of radium-223, and that number of
radium-223 doses was not a risk factor in thrombocytopenia
development.
Current treatment guidelines for CRPC and bone metastases
recommend radium-223 as a ﬁrst-line option in predocetaxel and
postdocetaxel settings.26-29 Analysis of outcomes for ALSYMPCA
patients who received chemotherapy (w70% of which was doce-
taxel) after completing the study-drug regimen (radium-223 or
placebo) identiﬁed no new hematologic concerns and no
Table 4 Stepwise Analysis of Grade 2-4 Anemia, Neutropenia, and Thrombocytopenia (Radium-223, Safety Population; N [ 600)
Baseline Variable
Anemia (N [ 567) Neutropenia (N [ 591) Thrombocytopenia (N [ 573)
Odds Ratio
(95% CI) P
Odds Ratio
(95% CI) P
Odds Ratio
(95% CI) P
4-6 injections vs. 1-3 injections 1.57 (0.92-2.69) .097 1.14 (0.32-4.12) .837 0.77 (0.38-1.56) .475
Age (years) per 1-year increasea 0.96 (0.92-0.99) .025
Extent of Disease
6-20 metastases vs. <6 metastases 2.76 (1.16-6.57) .022
>20 metastases vs. <6 metastases 2.78 (1.14-6.78) .025
Superscanb vs. <6 metastases 2.55 (0.86-7.58) .093
Log baseline tALP per 10-fold increasec 2.00 (1.12-3.55) .019
Log baseline PSA per 10-fold increasec 1.65 (1.15-2.36) .006 1.83 (1.12-2.99) .016
Prior docetaxel use (yes/no) 1.49 (0.96-2.30) .077 3.44 (1.21-9.74) .020 2.16 (1.06-4.42) .035
WHO Ladder for Cancer Paind
1 vs. 3 1.50 (0.44-5.13) .522
2 vs. 3 3.58 (1.05-12.22) .042
Baseline hemoglobin per 1 unit decrease 1.84 (1.55-2.19) <.001 1.35 (1.08-1.68) .008
Baseline neutrophil per 1 unit decrease 2.01 (1.41-2.87) <.001
Baseline platelet per 100 unit decrease 1.44 (1.04-2.00) .030
Based on a logistic regression model. Odds ratios of > 1 represent an increase in risk associated with an increase in baseline variable. Odds ratios are relative risk for 1 unit increase in baseline
variable (for those without log transformation) or a 10-times increase (for those with log transformation).
Abbreviations: N ¼ number of radium-223 and placebo patients included in the model; PSA ¼ prostate-speciﬁc antigen; tALP ¼ total alkaline phosphatase; WHO ¼ World Health Organization.
aRelative increase in risk for an adverse event with respect to an increase in age of 1 year.
bSuperscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without renal and background activity.
cLog transformation was performed for baseline variables with heavily skewed distributions. A WHO ladder score of 1 indicates mild pain and no opioid use, 2 indicates moderate pain and occasional
opioid use, and 3 indicates severe pain and regular daily opioid use.
dAnalysis includes 12 patients in the radium-223 group and 2 patients in the placebo group with no pain or analgesic use at baseline.
Nicholas J. Vogelzang et aldetrimental effects of prior radium-223 on overall survival.30 Given
these ﬁndings and those of current analyses regarding the relation-
ship of radium-223 and prior docetaxel exposure to thrombocyto-
penia development, it may be prudent to consider radium-223 prior
to docetaxel, although close monitoring of hematologic parameters
may be required for patients who receive chemotherapy later in the
treatment sequence.
Conclusion
Hematologic AEs are manageable if recognized early and
handled with appropriate care, generally allowing continued
treatment for maximum beneﬁt. These ALSYMPCA data provide
guidance to clinicians and help place their clinical experience with
radium-223 into a broader context. Following recommendations
in the prescribing information,10 with insights from the current
analysis, may enhance appropriate patient management and
safety.
Clinical Practice Points
 In the phase III ALSYMPCA trial, radium-223 signiﬁcantly
improved overall survival and delayed time to ﬁrst symptomatic
skeletal event with a favorable safety proﬁle, leading to its
approval for the treatment of patients with CRPC and symp-
tomatic bone metastases and no visceral metastases
 Overall, radium-223 was well tolerated and had a favorable he-
matologic safety proﬁle with a low incidence of
myelosuppression Post hoc analyses identiﬁed baseline risk factors associated with
hematologic toxicities related to radium-223 treatment; prior
docetaxel therapy and decreased platelet and hemoglobin levels
were risk factors for grade 2-4 thrombocytopenia, and baseline
extent of disease (6-20 vs. < 6 bone metastases) and elevated
PSA were risk factors for grade 2-4 anemia; neutropenia events in
placebo patients were too few for a comparative analysis to assess
a relationship with treatment effect
 These baseline factors and thrombocytopenia occurrence are
clinical considerations important for patient management
 Insights provided in this post hoc analysis can serve as a guide for
clinicians to help carefully examine risk factors that may predict
hematologic toxicities and identify high-risk patients who may
beneﬁt from close monitoring
 The favorable safety proﬁle and unique mechanism of action of
radium-223 suggest that it is suitable for use in combination or
sequentially with other agentsAcknowledgments
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Figure 3 Patients With Grade 3 or 4 Thrombocytopenia. Quartile Distribution of Platelet Counts Over Time Based on Platelet Counts at
Screening for Patients Receiving Radium-223 (A) or Placebo (B); Time to Onset of Grade 3/4 Thrombocytopenia (C) by
Number of Injections of Radium-223 or Placebo Received Before Onset, and Duration of Thrombocytopenia (D) by Time
(Weeks) Since First Dose of Radium-223 or Placebo
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Supplemental Table 1 Number of Study-Drug Injections
Received by Patients in ALSYMPCA
(Safety Population; N [ 901)
No. of Study-Drug
Injections
No. (%) Patients With:
Radium-223
(N [ 600)
Placebo
(N [ 301)
1 18 (3) 21 (7)
2 37 (6) 36 (12)
3 48 (8) 37 (12)
4 60 (10) 34 (11)
5 49 (8) 29 (10)
6 387 (65) 145 (48)
Supplemental Figure 1 Time to First Blood Transfusion (Intent-to-Treat Population; N [ 921)
Abbreviations: CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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Supplemental Table 2 Univariate Analysis of Grades 2-4 Anemia, Neutropenia, and Thrombocytopenia (Radium-223, Safety Population; N [ 600)
Baseline Variable
Anemia (N [ 567) Neutropenia (N [ 591) Thrombocytopenia (N [ 573)
OR 95% CI P OR 95% CI P OR 95% CI P
Agea,b (years) per 1-year increase 0.99 0.97-1.01 .224 0.96 0.91-1.01 .103 0.96 0.93-1.00 .033
Prior docetaxel use (yes/no) 1.63 1.13-2.37 .009 3.03 1.21-9.21 .029 3.01 1.61-6.08 .001
Current use of bisphosphonates (yes/no) 1.32 0.92-1.89 .126 0.96 0.41-2.16 .930 1.60 0.92-2.78 .092
ECOG PSb
1 vs. 0 1.46 0.96-2.26 .080 1.66 0.65-5.11 .325 0.87 0.48-1.64 .653
>2 vs. 0 1.40 0.75-2.61 .287 0.95 0.13-4.58 .956 0.57 0.18-1.54 .300
Extent of Diseaseb
6-20 metastases vs. <6 metastases 5.35 2.52-13.22 <.001 0.95 0.34-3.07 .930 3.18 1.08-13.64 .064
>20 metastases vs. <6 metastases 7.22 3.37-17.97 <.001 0.74 0.23-2.56 .611 4.16 1.40-17.91 .023
Superscanc vs. <6 metastases 12.70 5.14-35.10 <.001 0.40 0.02-2.63 .416 4.66 1.22-22.56 .032
External Beam Radiotherapy
<12 weeks of screening (yes/no) 1.04 0.73-1.48 .830 1.12 0.50-2.54 .781 1.06 0.61-1.85 .844
WHO Ladder for Cancer Painb,d
1 vs. 3 0.53 0.35-0.79 .002 1.78 0.58-6.60 .336 0.54 0.29-0.99 .049
2 vs. 3 0.57 0.35-0.91 .019 3.60 1.20-13.28 .032 0.53 0.24-1.09 .094
Log baseline tALP per 10-fold increasee 5.56 3.50-9.00 <.001 1.17 0.43-3.02 .758 1.91 0.99-3.65 .051
Log baseline LDH per 10-fold increaseb,e 8.07 3.68-18.08 <.001 0.89 0.14-5.03 .902 1.36 0.41-4.30 .612
Log baseline PSA per 10-fold increaseb,e 2.58 1.91-3.54 <.001 1.48 0.78-2.82 .232 2.22 1.42-3.54 .001
Baseline albuminb per 1 unit decrease 1.07 1.03-1.12 <.001 1.00 0.92-1.09 .950 1.03 0.97-1.09 .359
Baseline hemoglobinb per 1 unit decrease 2.12 1.82-2.50 <.001 1.07 0.81-1.42 .626 1.36 1.12-1.66 .002
Baseline neutrophilb per 1 unit decrease 0.96 0.89-1.04 .343 2.17 1.55-3.22 <.001 1.09 0.95-1.26 .248
Baseline plateletb per 100 unit decrease 0.79 0.65-0.95 .015 1.17 0.75-1.96 .513 1.20 0.87-1.69 .283
Based on a logistic regression model. Odds ratios of > 1 represent an increase in risk associated with an increase in baseline variable. Odds ratios are relative risk for 1 unit increase in baseline variable (for those without log transformation) or a 10-times increase (for those with
log transformation). Analyses include adjustment for treatment effect.
Abbreviations: ECOG PS ¼ Eastern Cooperative Oncology Group performance status; LDH ¼ lactate dehydrogenase; N ¼ number of patients included in the model; OR ¼ odds ratio; PSA ¼ prostate-speciﬁc antigen; tALP ¼ total alkaline phosphatase; WHO ¼ World Health
Organization.
aRelative increase in risk for an adverse event with respect to an increase in age of 1 year.
bALSYMPCA was not randomized by age, ECOG PS, extent of disease, WHO pain score subgroups, LDH, PSA, albumin, hemoglobin, or neutrophil or platelet counts, and results may be due to chance.
cSuperscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without renal and background activity.
dAnalysis includes 12 patients in the radium-223 group with no pain or analgesic use at baseline. A WHO ladder score of 1 indicates mild pain and no opioid use, 2 indicates moderate pain and occasional opioid use, and 3 indicates severe pain and regular daily opioid use.
eLog transformation was performed for baseline variables with heavily skewed distributions.
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Supplemental Table 3 Multivariate Analysis of Grades 2-4 Anemia, Neutropenia, and Thrombocytopenia (Radium-223, Safety Population; N [ 600)
Baseline Variable
Anemia (N [ 567) Neutropenia (N [ 591) Thrombocytopenia (N [ 573)
OR 95% CI P OR 95% CI P OR 95% CI P
4-6 injections vs. 1-3 injections 1.64 0.94-2.86 .080 1.14 0.32-4.12 0.837 0.82 0.40-1.67 .590
Agea,b (years) per 1-year increase 0.96 0.92-1.00 .033
Prior docetaxel use (yes/no) 1.39 0.88-2.18 .157 3.44 1.21-9.74 .020 1.98 0.96-4.11 .066
Current use of bisphosphonates (yes/no) 1.41 0.77-2.58 .271
Extent of Diseaseb
6-20 metastases vs. <6 metastases 2.75 1.15-6.58 .023 3.30 0.73-14.82 .119
>20 metastases vs. <6 metastases 2.73 1.11-6.71 .029 2.87 0.62-13.26 .178
Superscanc vs. <6 metastases 2.63 0.87-7.96 .087 2.02 0.35-11.71 .432
WHO Ladder for Cancer Painb,d
1 vs. 3 0.74 0.46-1.22 .238 1.50 0.44-5.13 .522 0.65 0.33-1.29 .217
2 vs. 3 0.72 0.41-1.27 .255 3.58 1.05-12.22 .042 0.64 0.28-1.45 .280
Log baseline tALP per 10-fold increasee 1.89 1.03-3.47 .041 1.12 0.48-2.61 .794
Log baseline LDH per 10-fold increaseb,e 1.31 0.49-3.48 .592
Log baseline PSA per 10-fold increaseb,e 1.63 1.13-2.34 .008 1.81 1.09-3.00 .022
Baseline albuminb per 1 unit decrease 0.99 0.95-1.04 .829
Baseline hemoglobinb per 1 unit decrease 1.81 1.51-2.17 <.001 1.30 1.02-1.66 .032
Baseline neutrophilb per 1 unit decrease 2.01 1.41-2.87 <.001
Baseline plateletb per 100 unit decrease 0.92 0.74-1.16 .494 1.53 1.07-2.17 .019
Based on a logistic regression model. Odds ratios of > 1 represent an increase in risk associated with an increase in baseline variable. Odds ratios are relative risk for 1 unit increase in baseline variable (for those without log transformation) or a 10-times increase (for those with
log transformation). Analyses include adjustment for treatment effect.
Abbreviations: LDH ¼ lactate dehydrogenase; N ¼ number of patients included in the model; OR ¼ odds ratio; PSA ¼ prostate-speciﬁc antigen; tALP ¼ total alkaline phosphatase; WHO ¼ World Health Organization.
aRelative increase in risk for an adverse event with respect to an increase in age of 1 year.
bALSYMPCA was not randomized by age, extent of disease, WHO pain score subgroups, LDH, PSA, albumin, hemoglobin, or neutrophil or platelet counts, and results may be due to chance.
cSuperscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without renal and background activity.
dAnalysis includes 12 patients in the radium-223 group with no pain or analgesic use at baseline. A WHO ladder score of 1 indicates mild pain and no opioid use, 2 indicates moderate pain and occasional opioid use, and 3 indicates severe pain and regular daily opioid use.
eLog transformation was performed for baseline variables with heavily skewed distributions.
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Supplemental Table 4 Univariate Analysis of Grades 2-4 Anemia and Thrombocytopenia (Placebo Patients, Safety Population;
N [ 301)a
Baseline Variable
Anemia (N [ 290) Thrombocytopenia (N [ 292)
OR 95% CI P OR 95% CI P
Age (years)b,c per 1-year increase 0.96 0.93-0.99 .023 0.93 0.86-0.99 .037
Prior docetaxel use (yes/no) 1.73 1.03-2.95 .042 2.63 0.79-11.91 .148
Current use of bisphosphonates (yes/no) 0.93 0.55-1.55 .774 0.94 0.28-2.89 .916
ECOG PSc
1 vs. 0 1.60 0.86-3.09 .149 0.98 0.26-4.65 .978
2 vs. 0 1.84 0.77-4.35 .167 1.30 0.17-8.15 .780
Extent of Diseasec
6-20 metastases vs. <6 metastases 4.57 1.29-29.10 .044
>20 metastases vs. <6 metastases 11.02 3.08-70.58 .002
Superscand vs. <6 metastases 20.00 4.87-137.56 <.001
External Beam Radiotherapy
12 weeks of screening (yes/no) 0.89 0.54-1.48 .659 0.93 0.29-2.87 .901
WHO Ladder for Cancer Painc,e
1 vs. 3 0.66 0.36-1.19 .162 0.60 0.14-2.62 .485
2 vs. 3 0.62 0.31-1.23 .174 1.39 0.35-5.79 .635
Log baseline tALP per 10-fold increasef 6.26 3.20-12.81 <.001 1.18 0.29-4.41 .812
Log baseline LDH per 10-fold increasec,f 2.54 0.96-6.75 .060 2.13 0.24-14.14 .459
Log baseline PSA per 10-fold increasec,f 2.40 1.58-3.74 <.001 8.46 2.87-29.88 <.001
Baseline albuminc per 1 unit decrease 1.03 0.98-1.09 .283 1.00 0.88-1.12 .967
Baseline hemoglobinc per 1 unit decrease 1.71 1.40-2.10 <.001 1.10 0.75-1.65 .624
Baseline neutrophilc per 1 unit decrease 1.01 0.90-1.15 .864 0.87 0.69-1.14 .273
Baseline plateletc per 100 unit decrease 0.75 0.57-0.99 .040 1.76 0.87-3.99 .148
Based on a logistic regression model. Odds ratios of > 1 represent an increase in risk associated with an increase in baseline variable. Odds ratios are relative risk for 1 unit increase in baseline
variable (for those without log transformation) or a 10-times increase (for those with log transformation). Analyses include adjustment for treatment effect.
Abbreviations: ECOG PS ¼ Eastern Cooperative Oncology Group performance status; LDH ¼ lactate dehydrogenase; N ¼ number of patients included in the model; OR ¼ odds ratio; PSA ¼ prostate-
speciﬁc antigen; tALP ¼ total alkaline phosphatase; WHO ¼ World Health Organization.
aThere were too few placebo patients with events for any valid analysis.
bRelative increase in risk for an adverse event with respect to an increase in age of 1 year.
cALSYMPCA was not randomized by age, ECOG PS, extent of disease, WHO pain score subgroups, LDH, PSA, albumin, hemoglobin, or neutrophil or platelet counts, and results may be due to chance.
dSuperscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without renal and background activity.
eAnalysis includes 2 patients in the placebo group with no pain or analgesic use at baseline. A WHO ladder score of 1 indicates mild pain and no opioid use, 2 indicates moderate pain and occasional
opioid use, and 3 indicates severe pain and regular daily opioid use.
fLog transformation was performed for baseline variables with heavily skewed distributions.
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Supplemental Table 5 Multivariate Analysis of Grades 2-4 Anemia and Thrombocytopenia (Placebo, Safety Population; N [ 301)
Baseline Variable
Anemia (N [ 290) Thrombocytopenia (N [ 292)
OR 95% CI P OR 95% CI P
Age (years) per 1-year increasea,b 0.95 0.92-0.99 .025 .090 0.83-0.98 .014
Prior docetaxel use (yes/no) 1.18 0.61-2.25 .624
Extent of Diseaseb
6-20 metastases vs. <6 metastases 2.51 0.50-12.52 .263
>20 metastases vs. <6 metastases 4.49 0.88-22.92 .071
Superscanc vs. <6 metastases 6.21 1.06-36.29 .043
Log baseline tALP per 10-fold increased 3.43 1.38-8.53 .008
Log baseline LDH per 10-fold increaseb,d 0.34 0.09-1.27 .109
Log baseline PSA per 10-fold increaseb,d 1.39 0.82-2.36 .224 9.37 2.48-35.32 .001
Baseline hemoglobinb per 1 unit decrease 1.47 1.16-1.87 .001
Baseline plateletb per 100 unit decrease 0.74 0.53-1.02 .069 1.33 0.64-2.75 .439
Based on a logistic regression model. Odds ratios of > 1 represent an increase in risk associated with an increase in baseline variable. Odds ratios are relative risk for 1 unit increase in baseline
variable (for those without log transformation) or a 10-times increase (for those with log transformation). Analyses include adjustment for treatment effect.
Abbreviations: LDH ¼ lactate dehydrogenase; N ¼ number of patients included in the model; OR ¼ odds ratio; PSA ¼ prostate-speciﬁc antigen; tALP ¼ total alkaline phosphatase.
aRelative increase in risk for an adverse event with respect to an increase in age of 1 year.
bALSYMPCA was not randomized by, age, extent of disease, LDH, PSA, hemoglobin, or platelet counts, and results may be due to chance.
cSuperscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without renal and background activity.
dLog transformation was performed for baseline variables with heavily skewed distributions.
Supplemental Table 6 Stepwise Analysis of Grade 2-4 Anemia and Thrombocytopenia (Placebo, Safety Population; N [ 301)
Baseline Variable
Anemia (N [ 290) Thrombocytopenia (N [ 292)
OR (95% CI) P OR (95% CI) P
Age (years) per 1-year increasea,b 0.95 0.91-0.99 .015 0.90 0.83-0.98 .014
Extent of Diseaseb
6-20 metastases vs. <6 metastases 2.67 0.56-12.85 .220
>20 metastases vs. <6 metastases 5.20 1.06-25.48 .042
Superscanc vs. <6 metastases 7.01 1.24-39.47 .027
Log baseline tALP per 10-fold increaseb,d 3.67 1.50-8.97 .004
Log baseline LDH per 10-fold increaseb,d 0.32 0.09-1.21 .094
Log baseline PSA per 10-fold increaseb,d 9.37 2.48-35.32 .001
Baseline hemoglobinb per 1 unit decrease 1.52 1.20-1.91 <.001
Baseline plateletb per 100 unit decrease 0.77 0.56-1.06 .114 1.33 0.64-2.75 .439
Based on a logistic regression model. Odds ratios of > 1 represent an increase in risk associated with an increase in baseline variable. Odds ratios are relative risk for 1 unit increase in baseline
variable (for those without log transformation) or a 10-times increase (for those with log transformation). Analyses include adjustment for treatment effect.
Abbreviations: LDH ¼ lactate dehydrogenase; N ¼ number of patients included in the model; OR ¼ odds ratio; PSA ¼ prostate-speciﬁc antigen; tALP ¼ total alkaline phosphatase.
aRelative increase in risk for an adverse event with respect to an increase in age of 1 year.
bALSYMPCA was not randomized by age, extent of disease, LDH, PSA, hemoglobin, or platelet counts, and results may be due to chance.
cSuperscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without renal and background activity.
dLog transformation was performed for baseline variables with heavily skewed distributions.
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Supplemental Table 7 Baseline Characteristics of Patients
With Grade 3 or 4 Thrombocytopenia
Characteristica
Radium-223
(N [ 38)
Placebo
(N [ 6)
Age
Median (range), years 68 (49-86) 66 (61-72)
>75 years, n (%) 7 (18) 0 (0)
Race, n (%)
White 38 (100) 6 (100)
tALP Level, n (%)
<220 U/L 17 (45) 3 (50)
220 U/L 21 (55) 3 (50)
Current Use of Bisphosphonates at
Study Entry, n (%)
Yes 21 (55) 1 (17)
No 17 (45) 5 (83)
Prior Docetaxel Use, n (%)
Yes 31 (82) 5 (83)
No 7 (18) 1 (17)
ECOG PS,b n (%)
0 10 (26) 1 (17)
1 24 (63) 3 (50)
2 4 (11) 2 (33)
WHO Ladder for Cancer Pain
0-1 (no pain or mild pain;
no opioid use)
14 (37) 2 (33)
2 (moderate pain; occasional
opioid use)
8 (21) 3 (50)
3 (severe pain; regular daily
opioid use)
16 (42) 1 (17)
Extent of Disease, n (%)
<6 metastases 2 (5) 0
6-20 metastases 13 (34) 3 (50)
>20 metastases or superscanc 23 (61) 3 (50)
EBRT Within 12 Weeks of
Screening, n (%)
Yes 8 (21) 0
No 30 (79) 6 (100)
Biochemical Values, Median
(Range)d
Albumin, g/L 38 (27-48) 39 (31-46)
tALP, U/L 252 (79-2681) 288 (112-758)
LDH, U/L 300 (184-1575) 410 (142-1301)
PSA, mg/L 344 (12-4955) 1472 (145-3500)
Hematologic Values, Median
(Range)d
Hemoglobin, g/dL 11 (9-14) 12 (10-14)
Neutrophils (absolute), 109/L 4 (2-10) 5 (3-10)
Platelets, 109/L 229 (75-645) 173 (78-321)
Lymphocytes, 109/L 1 (0.5-3) 2 (0.8-3)
Supplemental Table 7 Continued
Characteristica
Radium-223
(N [ 38)
Placebo
(N [ 6)
Time since diagnosis of prostate cancer,
monthse
59 (10-173) 41 (17-64)
Time since diagnosis of bone
metastases, monthse
22 (8-83) 31 (17-64)
Abbreviations: EBRT ¼ external beam radiotherapy; ECOG PS ¼ Eastern Cooperative Oncology
Group performance status; LDH ¼ lactate dehydrogenase; PSA ¼ prostate-speciﬁc antigen;
tALP ¼ total alkaline phosphatase; WHO ¼ World Health Organization.
aPercentages may not sum to 100% due to rounding.
bValue recorded at screening.
cSuperscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without
renal and background activity.
dValue recorded at week 0. If this value was missing, then the value recorded at screening was
used. The normal values were as follows: albumin, 36-45 g/L; total alkaline phosphatase, 35-
105 U/L; lactate dehydrogenase, 115-225 U/L; prostate-speciﬁc antigen, 0-3.999 mg/L; he-
moglobin, 13.4-17.0 g/dL; neutrophils (absolute), 2-7.5  109/L; platelets, 150-350  109/L;
lymphocytes 1-4  109/L.
eCalculated relative to randomization; 1 month is regarded as 30 days.
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Supplemental Table 8 Demographics and Baseline Characteristics of Patients With Pancytopenia or Bone Marrow Failure Compared
With ITT Population
Characteristica
Pancytopenia Patientsb ITT Population
Radium-223 (N [ 13) Radium-223 (N [ 614) Placebo (N [ 307)
Age
Median (range), years 66 (57-78) 71 (49-90) 71 (44-94)
>75 years, n (%) 1 (8) 171 (28) 90 (29)
Race, n (%)
White 13 (100) 575 (94) 290 (95)
tALP Level, n (%)
<220 U/L 9 (69) 348 (57) 169 (55)
220 U/L 4 (31) 266 (43) 138 (45)
Current Use of Bisphosphonates at Study Entry, n (%)
Yes 6 (46) 250 (41) 124 (40)
No 7 (54) 364 (59) 183 (60)
Prior Docetaxel Use, n (%)
Yes 11 (85) 352 (57) 174 (57)
No 2 (15) 262 (43) 133 (43)
ECOG PS,c n (%)
0 2 (15) 165 (27) 78 (26)
1 11 (85) 371 (61) 187 (61)
2 0 77 (13) 41 (13)
WHO Ladder for Cancer Pain
0-1 (no pain or mild pain; no opioid use) 8 (62) 269 (44) 139 (45)
2 (moderate pain; occasional opioid use) 3 (23) 151 (25) 78 (25)
3 (severe pain; regular daily opioid use) 2 (15) 194 (32) 90 (29)
Extent of Disease, n (%)
<6 metastases 0 100 (16) 38 (12)
6-20 metastases 7 (54) 262 (43) 147 (48)
20 metastases or superscand 6 (46) 249 (41) 121 (39)
EBRT Within 12 Weeks of Screening, n (%)
Yes 0 99 (16) 48 (16)
No 13 (100) 515 (84) 259 (84)
Biochemical Values, Median (Range)e
Albuminf, g/L 38 (29-43) 40 (24-53) 40 (23-50)
tALP, U/L 172 (56-1095) 211 (32-6431) 223 (29-4805)
LDH, U/L 283 (179-1199) 315 (76-2171) 336 (132-3856)
PSA, mg/L 334 (22-1045) 146 (4-6026) 173 (2-14,500)
Hematologic Values, Median (Range)
Hemoglobin, g/dL 12.0 (9-15) 12.2 (9-16) 12.1 (9-16)
Neutrophilsg (absolute), 109/L 3.6 (2-7) 4.5 (1-17) 4.4 (1-12)
Platelets,g 109/L 219 (115-498) 244 (69-645) 240 (51-580)
Lymphocytesg (absolute), 109/L 1.1 (1-2) 1.3 (0.3-7) 1.4 (0.2-4)
Time since diagnosis of prostate cancer, monthsh 56 (10-135) 59 (8-313) 52 (1-347)
Time since diagnosis of bone metastases, monthsh 22 (0.3-89) 25 (0-254) 22 (0.2-183)
Abbreviations: EBRT ¼ external beam radiotherapy; ECOG PS ¼ Eastern Cooperative Oncology Group performance status; LDH ¼ lactate dehydrogenase; ITT ¼ intent to treat; PSA ¼ prostate-
speciﬁc antigen; tALP ¼ total alkaline phosphatase; WHO ¼ World Health Organization.
aPercentages may not sum to 100% due to rounding.
bIncludes patients with the preferred term pancytopenia or bone marrow failure.
cValue recorded at screening.
dSuperscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without renal and background activity.
eValue recorded at week 0. If this value was missing, then the value recorded at screening was used. Normal values were as follows: albumin, 36-45 g/L; tALP, 35-105 U/L; LDH, 115-225 U/L; PSA,
0-3.999 mg/L; hemoglobin, 13.4-17.0 g/dL; neutrophils (absolute), 2-7.5  109/L; platelets, 150-350  109/L; lymphocytes, 1-4  109/L.
fMedian (range) from 12 patients.
gSafety population.
hCalculated relative to randomization; 1 month is regarded as 30 days.
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Supplemental Table 9 Xoﬁgo Prescribing Information:
Recommended Absolute Neutrophil
and Platelet Counts Before Adminis-
tration of Radium-223 to Patients With
Castration-Resistant Prostate Cancer
and Symptomatic Bone Metastases
Injection Neutrophils Platelets
1 1.5  109/L 100  109/L
2-6 1.0  109/La 50  109/La
aIf no recovery to these values within 6 to 8 weeks after the last administration of radium-223
despite supportive care, further treatment with radium-223 should be discontinued.
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